The Mexican consensus on fecal incontinence

Rev Gastroenterol Mex (Engl Ed). 2023 Oct-Dec;88(4):404-428. doi: 10.1016/j.rgmxen.2023.08.003. Epub 2023 Dec 13.

Abstract

Fecal incontinence is the involuntary passage or the incapacity to control the release of fecal matter through the anus. It is a condition that significantly impairs quality of life in those that suffer from it, given that it affects body image, self-esteem, and interferes with everyday activities, in turn, favoring social isolation. There are no guidelines or consensus in Mexico on the topic, and so the Asociación Mexicana de Gastroenterología brought together a multidisciplinary group (gastroenterologists, neurogastroenterologists, and surgeons) to carry out the «Mexican consensus on fecal incontinence» and establish useful recommendations for the medical community. The present document presents the formulated recommendations in 35 statements. Fecal incontinence is known to be a frequent entity whose incidence increases as individuals age, but one that is under-recognized. The pathophysiology of incontinence is complex and multifactorial, and in most cases, there is more than one associated risk factor. Even though there is no diagnostic gold standard, the combination of tests that evaluate structure (endoanal ultrasound) and function (anorectal manometry) should be recommended in all cases. Treatment should also be multidisciplinary and general measures and drugs (lidamidine, loperamide) are recommended, as well as non-pharmacologic interventions, such as biofeedback therapy, in selected cases. Likewise, surgical treatment should be offered to selected patients and performed by experts.

Keywords: Biofeedback; Bioretroalimentación; Cirugía; Diarrea; Diarrhea; Fecal incontinence; Incontinencia fecal; Manometry; Manometría; Mexico; México; Surgery.

Publication types

  • Practice Guideline

MeSH terms

  • Consensus
  • Fecal Incontinence* / diagnosis
  • Fecal Incontinence* / etiology
  • Fecal Incontinence* / therapy
  • Humans
  • Loperamide / therapeutic use
  • Mexico / epidemiology
  • Quality of Life

Substances

  • Loperamide